Guizhou Bailing Group Pharmaceutical Co Ltd

Guizhou Bailing Group Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.39, indicating a relatively conservative capital structure. However, the company's current ratio of 0.97 suggests that it may struggle to meet short-term obligations with its current assets. The company reported negative net income of CNY -104.37 million, and its free cash flow was negative at CNY -166.56 million, indicating cash outflows from operations after capital expenditures. The company's return on equity (ROE) is -3.31%, and its return on assets (ROA) is -1.68%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating sufficient returns to cover its cost of capital or to justify its asset base. The negative net income and weak ROE/ROA indicate poor profitability and operational efficiency. Geographically, the company's revenue is concentrated in China, with no disclosed international operations. The company's revenue breakdown by product or segment is not available in the provided data, but the negative net income and weak operating income of CNY 78.67 million suggest that the company is not achieving strong performance in its core business lines. The lack of segment data limits the ability to assess the performance of individual product lines or geographic regions. Looking ahead, the company's growth trajectory is uncertain. The provided data does not include forward-looking revenue guidance or projections for the next fiscal year. The company's operating cash flow of CNY 748.72 million is positive, but it is not sufficient to offset the negative free cash flow. The company's capital expenditures of CNY -125.24 million indicate ongoing investment in infrastructure or production capacity, but the negative net income raises concerns about the sustainability of these investments. The company faces several risk factors, including liquidity risk due to its current ratio of 0.97 and the fact that its net cash is negative after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. However, the negative net income and weak operating performance could lead to future financing needs, which may result in share dilution. Recent events and disclosures do not provide specific details on the company's strategic initiatives or major business developments. The company's ESG score is 22.49, with a D+ rating, indicating poor environmental, social, and governance performance. The governance pillar score of 39.23 is the highest among the three ESG pillars, but it is still below the industry median. The company's ESG controversies score of 100 suggests that it has not been involved in any major controversies, but its overall ESG performance remains weak.